Committee debates HF 4349 on gene‑therapy reimbursement, requests fiscal note and lays bill over House File 4349 would unbundle one‑time gene and cell therapies from DRGs and allow, but not require, value‑based arrangements; members questioned 340B implications, acquisition‑cost reimbursement language, and managed‑care carve‑outs; a fiscal note was requested and the bill was laid over.

Minnesota lawmakers are diving deep into the complexities of gene therapy reimbursement, sparking intense debate over funding and fairness in healthcare.

Get the details!

#MN #MinnesotaHealthcare #CitizenPortal #HealthcareReform #PharmaceuticalAccess #ValueBasedCare

Committee approves bill to allow over-the-counter ivermectin if FDA approves The Health and Human Services Committee voted to pass Senate Bill 2014, which would permit ivermectin to be sold over the counter contingent on FDA approval; proponents said FDA would set dosing and dispensing guidelines and opponents recorded three nays in the 9–3 roll call.

Senate Bill 2014 has just passed, paving the way for over-the-counter sales of ivermectin—pending FDA approval—sparking a heated debate on safety and dosing guidelines.

Click to read more!

#OK #PublicHealth #CitizenPortal #RegulatoryReform #PharmaceuticalAccess

PBM and Insurer Groups Testify Against Bill Limiting Midyear Formulary Changes Opponents including the Pharmaceutical Care Management Association and Ohio Association of Health Plans told the Senate committee that Senate Bill 160, intended to limit nonmedical switching midyear, could raise costs for employers and plans and complicate formulary management.

New Senate Bill 160 aims to protect patients from nonmedical switching of prescriptions, but experts warn it could lead to higher costs for employers and patients alike.

Learn more here

#OH #CitizenPortal #CostManagement #HealthcarePolicy #PharmaceuticalAccess

Pharmaceutical Group Advocates for Transparency in Kansas 340B Program Group emphasizes tracking funding impacts and preserving contract pharmacies for rural care.

Kansas legislators are pushing for transparency in the 340B drug pricing program to ensure vital medications reach patients in rural areas.

Learn more here!

#KS #CitizenPortal #HealthcareTransparency #PatientSupport #KansasRuralHealth #PharmaceuticalAccess

Pennsylvania House Bill allows over-the-counter sale of ivermectin Pennsylvania's House Bill 1494 enables ivermectin to be sold OTC without prescriptions.

Pennsylvania just passed a groundbreaking bill allowing ivermectin to be sold over-the-counter, sparking debates across the nation!

Click to read more!

#PA #CitizenPortal #PennsylvaniaHealth #PublicHealth #LegislativeReform #PharmaceuticalAccess

Health Committee advances House Bill 2385 A amid transparency concerns Committee approves amendment to House Bill 2385 A while discussing transparency issues in healthcare.

Oregon lawmakers are at a crossroads, debating a crucial bill aimed at increasing transparency in pharmaceutical delivery that could reshape healthcare for many.

Click to read more!

#OR #HealthcareTransparency #CivicAccountability #PharmaceuticalAccess

Oregon House passes bill regulating 340B drugs and insurer practices Legislation mandates study on healthcare and establishes rules for insurers regarding 340B drugs

Oregon just passed groundbreaking legislation to regulate 340B drugs and reshape insurer practices in healthcare!

Read the full story

#OR #PharmaceuticalAccess #HealthcareRegulation